Samsung Bioepis Patent-Cliff Exposure & CMS Drug Spending Portfolio
Samsung Bioepis (US): 8 reconciled FDA prescription therapies, $53.2M 2024 CMS Part D & Medicaid spend, and $5,830 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 8 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $53.2M |
| 2024 Medicare Part D Spend | $12.5M |
| 2024 Medicaid Spend | $40.6M |
| California HCAI SB 17 Filings | Specialty launch notice ($5,830 intro WAC) |